NSE · Healthcare · Drug Manufacturers - Specialty & Generic
with an average price target of ₹2,765.00.
| Document | Date |
|---|---|
| Annual report FY2026 CAPLIN POINT LABORATORIES LIMITED - ANNUAL REPORT FY2025-26 SUMMARY HEADLINE NUMBERS • Operating Revenue FY26: ₹2,187.19 Crores | 12.89% Y-o-Y growt | 2026-09-03 |
| Q1 FY27 earnings call DOCUMENT SUMMARY: CAPLIN POINT LABORATORIES LIMITED IMPORTANT NOTE This document is a regulatory filing notifying stock exchanges about the availabil | 2026-08-19 |
| Investor presentation · Q1 FY27 CAPLIN POINT LABORATORIES LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Q1 FY27 Consolidated Revenue from Operations: ₹610.4 Crores, up 19.6% YoY (Q | 2026-08-12 |
| Quarterly results · Q1 FY27 CAPLIN POINT LABORATORIES LIMITED - DOCUMENT SUMMARY HEADLINE NUMBERS • Q1 FY27 Consolidated Revenue: ₹643.91 crores, up 20.7% YoY (₹533.36 crores i | 2026-08-12 |
| Q4 FY26 earnings call DOCUMENT SUMMARY: CAPLIN POINT LABORATORIES LIMITED IMPORTANT NOTE This document is a regulatory filing notification, not a financial results documen | 2026-05-21 |
| Quarterly results · Q4 FY26 CAPLIN POINT LABORATORIES LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Interim Dividend: INR 4.00 per share (200% of face value of INR 2), Record | 2026-05-14 |
| Q3 FY26 earnings call CAPLIN POINT LABORATORIES LIMITED - DOCUMENT SUMMARY HEADLINE INFORMATION • Document is a regulatory filing dated February 11, 2026 from Caplin Poin | 2026-02-11 |
| Quarterly results · Q3 FY26 CAPLIN POINT LABORATORIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q3 FY26 Consolidated Revenue from Operations: ₹542.8 Crores (10.1% YoY grow | 2026-02-05 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹4 / share ex-date Sep 18, 2026 | 2026-09-18 |
| Dividend | ₹4 / share ex-date May 29, 2026 · record May 30, 2026 | 2026-05-29 |
| Dividend | ₹3 / share ex-date Sep 12, 2025 | 2025-09-12 |
| Announcement | Date |
|---|---|
| Acquisition of ANDAs announced Caplin Point Laboratories, a pharmaceutical company, announced the acquisition of ANDAs (Abbreviated New Drug Applications). ANDAs are regulatory approvals from the US FDA that allow generic | 2026-01-01 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Caplin Point Laboratories Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.